Honeybee venom immunotherapy: Certainties and pitfalls

Immunotherapy

Volumn 4, Issue 11, 2012, Pages 1153-1166

  Bilò, M Beatrice ^a   Antonicelli, Leonardo ^a   Bonifazi, Floriano ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

beekeeper; build up phase protocol; efficacy; future strategies; honeybee; mechanisms; recombinant venom allergens; relapse; risk factors; safety; venom immunotherapy

Indexed keywords

ACID PHOSPHATASE; ALLERGEN; ANTIHISTAMINIC AGENT; BEE VENOM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOXYLESTERASE; CUB SERINE PROTEASE; CYSTEINE RICH TRYPSIN INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; ESTERASE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYALURONIDASE; ICARAPIN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; INSECT PROTEIN; MAJOR ROYAL JELLY PROTEIN; MELITTIN; OMALIZUMAB; PHOSPHOLIPASE A2; SERINE CARBOXYLESTERASE; SERINE PROTEINASE; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; VITELLOGENIN;

ANGIONEUROTIC EDEMA; ANTIBODY TITER; BASOPHIL ACTIVATION TEST; BEE; BEEKEEPER; CELL POPULATION; CELLULAR ANTIGEN STIMULATION TEST; CLINICAL PROTOCOL; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SENSITIZATION; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; HISTORY; HONEYBEE; HONEYBEE VENOM ALLERGY; HUMAN; HYMENOPTERA; IMMUNE FUNCTION TEST; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INSECT ALLERGY; INSECT STING; MASTOCYTOSIS; MOLECULAR DIAGNOSIS; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RISK FACTOR; RISK REDUCTION; SKIN TEST; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; SYSTEMIC MASTOCYTOSIS; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT INDICATION; URTICARIA; VENOM IMMUNOTHERAPY;

ALLERGENS; ANAPHYLAXIS; ANIMALS; BEE VENOMS; BEEKEEPING; CLINICAL PROTOCOLS; DESENSITIZATION, IMMUNOLOGIC; EUROPE; HUMANS; HYPERSENSITIVITY; OCCUPATIONAL DISEASES; PREVALENCE; RISK; UNITED STATES;

EID: 84870399210     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.113     Document Type: Review

References (86)

1. Bilò BM, Ruëff F, Mosbech H, Bonifazi F, Oude Elberink JNG. The EAACI Interest Group on insect venom hypersensitivity: diagnosis of hymenoptera venom allergy. Allergy 60, 1339-1349 (2005).
2. Bilò MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin. Exp. Allergy 39, 1467-1476 (2009).
3. Brown TC, Tankersley MS. The sting of the honeybee: an allergic perspective. Ann. Allergy Asthma Immunol. 107, 463-470 (2011).
4. Novembre E, Cianferoni A, Bernardini R et al. Epidemiology of insect venom sensitivity in children and its correlation to clinical and atopic features. Clin. Exp. Allergy 28, 834-838 (1998).
5. Marques L, Vega A, Munoz E, Moreno-Ancillo A. Epidemiologic observations on Hymenoptera allergy in Spain: the alergologica-2005 study. J. Investig. Allergol. Clin. Immunol. 19, 51-55 (2009).
6. Prado M, Quiros D, Lomonte B. Mortality due to Hymenoptera stings in Costa Rica, 1985-2006. Pan Am. J. Public Health 25, 389-393 (2009).
7. Müller U. Bee venom allergy in beekeepers and their family members. Curr. Opin Allergy Clin. Immunol. 5, 343-347 (2005).
8. Celikel S, Karakaya G, Yurtsever N, Sorkun K, Kalyoncu AF. Bee and bee products allergy in Turkish beekeepers: determination of risk factors for systemic reactions. Allergol. Immunopathol. (Madr.). 180-184 (2006).
9. Richter AG, Nightingale P, Huissoon AP, Krishna MT. Risk factors for systemic reactions to bee venom in British beekeepers. Ann. Allergy Asthma Immunol. 106, 159-163 (2011).
10. Eich-Wanger C, Müller UR. Bee sting allergy in beekeepers. Clin. Exp. Allergy. 28, 1292-1298 (1998).
11. Müller UR. Hymenoptera venom proteins and peptides for diagnosis and treatment of venom allergic patients. Inflamm. Allergy Drug Targets 10, 420-428 (2011).
12. Francese S, Lambardi D, Mastrobuoni G, la Marca G, Moneti G, Turillazzi S. Detection of honeybee venom in envenomated tissues by direct MALDI MSI. J. Am. Soc. Mass. Spectrom. 20, 112-123 (2009).
13. Mustafa FB, Ng FS, Nguyen TH, Lim LH. Honeybee venom secretory phospholipase A2 induces leukotriene production but not histamine release from human basophils. Clin. Exp. Immunol. 151, 94-100 (2008).
14. Markovi-Housley Z, Miglierini G, Soldatova L, Rizkallah PJ, Müller U, Schirmer T. Crystal structure of hyaluronidase, a major allergen of bee venom. Structure 15(8), 1025-1035 (2000).
15. Jin C, Focke M, Léonard R, Jarisch R, Altmann F, Hemmer W. Reassessing the role of hyaluronidase in yellow jacket venom allergy. J. Allergy Clin. Immunol. 125, 184-190 (2010).
16. Grunwald T, Bockisch B, Spillner E, Ring J, Bredehorst R, Ollert MW. Molecular cloning and expression in insect cells of honeybee venom allergen acid phosphatase (Api m 3). J. Allergy Clin. Immunol. 117, 848-854 (2006).
17. Seppälä U, Francese S, Turillazzi S, Moneti G, Clench M, Barber D. In situ imaging of honeybee (Apis mellifera) venom components from aqueous and aluminum hydroxide-adsorbed venom immunotherapy preparations. J. Allergy Clin. Immunol. 129, 1314-1320 (2012).
18. Winningham KM, Fitch CD, Schmidt M, Hoffman DR. Hymenoptera venom protease allergens. J. Allergy Clin. Immunol. 114, 928-933 (2004).
19. Blank S, Seismann H, Bockisch B et al. Identification, recombinant expression, and characterization of the 100 kDa high molecular weight Hymenoptera venom allergens Api m 5 and Ves v 3. J. Immunol. 1(184), 5403-5413 (2010).
20. Blank S, Seismann H, Michel Y et al. Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts. Allergy 66, 1322-1329 (2011).
21. Ozdemir C, Kucuksezer UC, Akdis M, Akdis CA. Mechanisms of immunotherapy to wasp and bee venom. Clin. Exp. Allergy 41, 1226-1234 (2011).
22. Jutel M, Akdis CA. T-cell regulatory mechanisms in specific immunotherapy. Chem. Immunol. Allergy 94, 158-171 (2008).
23. Akdis CA, Akdis M, Blesken T et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. Clin. Invest. 98, 1676-1683 (1996).
24. Bussmann C, Xia J, Allam JP, Maintz L, Bieber T, Novak N. Early markers for protective mechanisms during rush venom immunotherapy. Allergy 65, 1558-1565 (2010).
25. Jutel M, Müller U, Fricker M, Rihs S, Pichler WJ, Dahinden C. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin. Exp. Allergy 26, 1112-1118 (1996).
26. Goldberg A, Confino-Cohen R. Bee venom immunotherapy-how early is it effective? Allergy 65, 391-395 (2010).
27. Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Muller U. EAACI Interest Group on insect venom hypersensitivity: prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 60, 1459-1470 (2005).
28. Bilò BM, Bonifazi F. Hymenoptera venom immunotherapy. Immunotherapy 3, 229-224 (2011).
29. Golden DB, Moffitt J, Nicklas RA et al. Stinging insect hypersensitivity: a practice parameter update 2011. J. Allergy Clin. Immunol. 127, 852-854, E1-E23 (2011).
30. Müller UR, Johansen N, Petersen AB, Fromberg-Nielsen J, Haeberli G. Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m1 and Ves v5. Allergy 64, 543-548 (2009).
31. Hofmann SC, Pfender N, Weckesser S, Huss-Marp J, Jakob T. Added value of IgE detection to rApi m 1 and rVes v 5 in patients with Hymenoptera venom allergy. J. Allergy Clin. Immunol. 127, 265-267 (2011).
32. Korošec P, Valenta R, Mittermann I et al. Low sensitivity of commercially available rApi m1 for diagnosis of honeybee venom allergy. J. Allergy Clin. Immunol. 128, 671-673 (2011).
33. Sturm GJ, Hemmer W, Hawranek T et al. Detection of IgE to recombinant Api m 1 and rVes v 5 is valuable but not sufficient to distinguish bee from wasp venom allergy. J. Allergy Clin. Immunol. 128, 247-248 (2011).
34. Sturm GJ, Biló MB, Bonadonna P et al. Ves v 5 can establish the diagnosis in patients without detetable sIgE to wasp venom and a possible north-south difference in Api m1 sensitization in Europe. J. Allergy Clin. Immunol. 130(3), 817 (2012).
35. Müller U, Schmid-Grendelmeier P, Hausmann O, Helbling A. IgE to recombinant allergens Api m 1, Ves v 1, and Ves v 5 distinguish double sensitization from cross reaction in venom allergy. Allergy 67, 1069-1073 (2012).
36. Jakob T, Köhler J, Blank S et al. Comparable IgE reactivity to natural and recombinant Api m1 in cross-reactive carbohydrate determinant-negative patients with bee venom allergy. J. Allergy Clin. Immunol. 130, 276-278 (2012).
37. Mittermann I, Zidarn M, Silar M et al. Recombinant allergen-based IgE testing to distinguish bee and wasp allergy. J. Allergy Clin. Immunol. 125, 1300-1307 (2010).
38. Mertens M, Brehler R. Suitability of different glycoproteins and test systems for detecting cross-reactive carbohydrate determinant-specific IgE in hymenoptera venom-allergic patients. Int. Arch. Allergy Immunol. 156, 43-50 (2011).
39. Korosec P, Erzen R, Silar M, Bajrovic N, Kopac P, Kosnik M. Basophil responsiveness in patients with insect sting allergies and negative venom-specific immunoglobulin E and skin prick test results. Clin. Exp. Allergy 39, 1730-1737 (2009).
40. Przybilla B, Ruëff F. Hymenoptera venom allergy. J. Dtsch Dermatol. Ges. 8, 114-129 (2010).
41. Severino MG, Cortellini G, Bonadonna P et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 122, 44-48 (2008).
42. Blaauw PJ, Smithuis LO. The evaluation of the common diagnostic methods of hypersensitivity for bee and yellow jacket venom by means of an in-hospital insect sting. J. Allergy Clin. Immunol. 75, 556-562 (1985).
43. van der Linden PW, Hack CE, Struyvenberg A, van der Zwan JK. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J. Allergy Clin. Immunol. 94, 151-159 (1994).
44. Ruëff F, Przybilla B, Biló MB et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on insect venom hypersensitivity. J. Allergy Clin. Immunol. 124, 047-054 (2009).
45. González-de-Olano D, Alvarez-Twose I, Vega A, Orfao A, Escribano L. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy 3, 637-651 (2011).
46. Bonadonna P, Perbellini O, Passalacqua G et al. Clonal mast cell disorders in patients with systemic reactions to hymenoptera stings and increased serum tryptase levels. J. Allergy Clin. Immunol. 123, 680-686 (2009).
47. Krishna MT, Ewan PW, Diwakar L et al. British Society for Allergy and Clinical Immunology. Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines. Clin. Exp. Allergy 41, 1201-1220 (2011).
48. Müller UR. Cardiovascular disease and anaphylaxis. Curr. Opin Allergy Immunol. 7, 337-341 (2007).
49. Golden DB, Kelly D, Hamilton RG, Craig TJ. Venom immunotherapy reduces large local reactions to insect stings. J. Allergy Clin. Immunol. 123, 1371-1375 (2009).
50. Muller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J. Allergy Clin. Immunol. 89, 529-535 (1992).
51. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: a meta-analysis. Clin. Ther. 22, 351-358 (2000).
52. Watanabe AS, Fonseca LA, Galvao CE, Kalil J, Castro FF. Specific immunotherapy using hymenoptera venom: systematic review. Sao Paulo Med. J. 128, 30-37 (2010).
53. Houliston L, Nolan R, Noble V et al. Honeybee venom immunotherapy in children using a 50-mg maintenance dose. J. Allergy Clin. Immunol. 127, 98-999 (2011).
54. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J. Allergy Clin. Immunol. 108, 1027-1032 (2001).
55. Goldberg A, Yogev A, Confino-Cohen R. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective. Int. Arch. Allergy Immunol. 156, 90-98 (2011).
56. Bilò MB, Cinti B, Brianzoni MF, Braschi MC, Bonifazi M, Antonicelli L. Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal basal serum tryptase concentrations. J. Allergy (Cairo). 2012, 869243 (2012).
57. Roumana A, Pitsios C, Vartholomaios S, Kompoti E, Kontou-Fili K. The safety of initiating Hymenoptera immunotherapy at 1 μg of venom extract. J. Allergy Clin. Immunol. 124, 379-381 (2009).
58. Bilò MB, Antonicelli L, Bonifazi F. Purified versus nonpurified venom immunotherapy. Curr. Opin Allergy Clin. Immunol. 10, 89330-89336 (2010).
59. Cavallucci E, Ramondo S, Renzetti A et al. Maintenance venom immunotherapy administered at a 3-month interval preserves safety and efficacy and improves adherence. J. Investig. Allergol. Clin. Immunol. 20, 63-68 (2010).
60. Goldberg A, Confino-Cohen R. Effectiveness of maintenance bee venom immunotherapy administered at 6-month intervals. Ann. Allergy Asthma Immunol. 99, 352-357 (2007).
61. Žitnik SE, Vesel T, Avin T, Šilar M, Košnik M, Korošec P. Monitoring honeybee venom immunotherapy in children with the basophil activation test. Pediatr. Allergy Immunol. 23, 166-172 (2012).
62. Incorvaia C, Frati F, Dell'Albani I et al. Safety of hymenoptera venomimmunotherapy: a systematic review. Expert Opin Pharmacother. 12, 2527-2532 (2011).
63. Ruëff F, Przybilla B, Biló MB et al. European Academy of Allergy and Clinical Immunology Interest Group. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J. Allergy Clin. Immunol. 126, 105-111 (2010).
64. Patella V, Florio G, Giuliano A et al. Hymenoptera venom immunotherapy: tolerance and efficacy of an ultrarush protocol versus a rush and a slow conventional protocol. J. Allergy (Cairo) 2012, 192192 (2012).
65. Kalogeromitros D, Makris M, Koti I et al. A simple 3-day "rush" venom immunotherapy protocol: documentation of safety. Allergol. Immunopathol. 38, 69-73 (2010).
66. Müller UR, Haeberli G. Use of b-blockers during immunotherapy for Hymenoptera venom allergy. J. Allergy Clin. Immunol. 115, 606-610 (2005).
67. Müller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J. Allergy Clin. Immunol. 107, 81-86 (2001).
68. Müller UR, Jutel M, Reimers A et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J. Allergy Clin. Immunol. 122, 1001-1007 (2008).
69. Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J. Investig. Allergol. Clin. Immunol. 19, 225-229 (2009).
70. Gomis VS, Delgado PG, Hernandez EN. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J. Investig. Allergol. Clin. Immunol. 18, 225-226 (2008).
71. Rueff F, Bilo MB, Jutel M, Mosbech H, Muller U, Przybilla B. Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy. J. Allergy Clin. Immunol. 123, 272-273 (2009).
72. Ruëff F, Wolf H, Schnitker J et al. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. Allergy 59, 589-595 (2004).
73. Bilò MB, Severino M, Cilia M et al. The VISYT trial: venom immunotherapy safety and tolerability with purified vs nonpurified extracts. Ann. Allergy Asthma Immunol. 103, 57-61 (2009).
74. Muller U, Berchtold E, Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J. Allergy Clin. Immunol. 87, 702 (1991).
75. Lerch E, Muller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J. Allergy Clin. Immunol. 101, 606-612 (1998).
76. Golden DB. Long-term outcome after venom immunotherapy. Curr. Opin Allergy Clin. Immunol. 10, 337-341 (2010).
77. Hockenhull J, Elremeli M, Cherry MG et al. A systematic review of the clinical effectiveness and cost effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy. Health Technol. Assess. 16, III-IV, 1-110 (2012).
78. Münstedt K, Wrobel D, Kalder M. Efficacy of venom immunotherapy in beekeepers. J. Investig. Allergol. Clin. Immunol. 20, 58-62 (2010).
79. Müller UR. Recent developments and future strategies for immunotherapy of insect venom allergy. Curr. Opin Allergy Clin. Immunol. 3, 299-303 (2003).
80. Fellrath JM, Kettner A, Dufour N et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J. Allergy Clin. Immunol. 111, 854-861 (2003).
81. Jilek S, Barbey C, Spertini F, Corthesy B. Antigen independent suppression of the allergic immune response to bee venom phospholipase A2 by DNA vaccination in CBA/J mice. Immunology 166, 3612-3621 (2001).
82. Kussebi F, Karamloo F, Rhyner C et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J. Allergy Clin. Immunol. 115, 323-329 (2005).
83. Karamloo F, Schmid-Grendelmeier P, Kussebi F et al. Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur. J. Immunol. 35, 3268-3276 (2005).
84. Müller UR, Akdis CA, Fricker M et al. Successful immunotherapy with T cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in bee sting allergic patients. J. Allergy Clin. Immunol. 101, 747-754 (1998).
85. Senti G, Prinz Vavricka BM, Erdmann I et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc. Natl Acad. Sci. USA 105, 17908-17912 (2008).
86. Senti G, Johansen P, Kündig TM. Intralymphatic immunotherapy. Curr. Opin Allergy Clin. Immunol. 9, 537-543 (2009).